Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

Niklas Gebauer*, Harald Biersack, Ann Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Veronica Bernard, Dirk Rades, Hendrik Lehnert, Kim Barbara Luley, Christoph Thorns

*Corresponding author for this work
1 Citation (Scopus)
Original languageEnglish
JournalLeukemia and Lymphoma
Issue number6
Pages (from-to)1482-1486
Number of pages5
Publication statusPublished - 02.06.2016

Cite this